Lexaria Bioscience Corp. has engaged a contract research organization to execute Human Pilot Study #7, which will evaluate two oral DehydraTECH-semaglutide compositions against commercially available Wegovy tablets. The study represents a significant advancement in Lexaria's drug delivery platform development, with contracts signed and ethics approval submissions currently being prepared.
The study design is expected to be a 5-week parallel group investigation with three separate arms to assess safety, tolerability, and pharmacokinetic properties. This research will compare salcaprozate sodium-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy tablets under fasted pre-dose conditions. Lexaria aims to preserve the superior safety and tolerability profiles demonstrated in previous GLP-1 studies while achieving pharmacokinetic performance that matches or exceeds commercial oral tablet brands Rybelsus and Wegovy.
This study explores several new DehydraTECH enhancements not previously evaluated. For the first time, Lexaria is using an oral tablet DHT-sema composition, as opposed to the capsule compositions included in all previous DHT glucagon-like peptide-1 studies. The company has attempted to mimic certain properties of the Rybelsus and Wegovy tablet delivery modality into its DHT-sema tablets. Both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, marking the first time these formulations are evaluated over a multi-dose, multi-week time period in humans.
The 5-week duration of the study is expected to be long enough to reach steady-state, when drug concentrations in the body reach a constant concentration. Earlier DHT-sema human pilot studies that Lexaria conducted in 2024 and 2025 that also used SNAC were limited by single-dose study designs of much shorter duration. Novo Nordisk's branded Rybelsus and Wegovy semaglutide-based products are both formulated with SNAC.
If successful, the study results will be additive to an already impressive data set aimed at generating interest from pharmaceutical partners seeking to enter into commercial relationships encompassing Lexaria's proprietary DehydraTECH technology. DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream through oral delivery. The technology has demonstrated the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier.
Lexaria will update stakeholders once ethics board approval for the study has been achieved, at which time patient recruitment can begin. The study is fully funded from existing corporate resources. For more information about the company and its technology platform, visit https://www.lexariabioscience.com. The original release can be viewed at https://www.newmediawire.com.
